<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duffel</td>
<td>Erika</td>
<td>ECDC</td>
</tr>
<tr>
<td>Logtenberg-van der Grient</td>
<td>Hilje</td>
<td>ELPA</td>
</tr>
<tr>
<td>Kane</td>
<td>Mark</td>
<td>Ex WHO, Ex GAVI</td>
</tr>
<tr>
<td>Wiktor</td>
<td>Stefan</td>
<td>WHO</td>
</tr>
<tr>
<td>Lavanchy</td>
<td>Daniel</td>
<td>WHO</td>
</tr>
<tr>
<td>Emiroglu</td>
<td>Nedret</td>
<td>WHO Euro</td>
</tr>
<tr>
<td>Mosina</td>
<td>Liudmila</td>
<td>WHO Euro</td>
</tr>
<tr>
<td>FitzSimons</td>
<td>David</td>
<td>Ex WHO</td>
</tr>
</tbody>
</table>
What is the focus of your organisation on viral hepatitis in the coming 5 years

- WHO: development of global strategy
- WHO EURO: implementation of the European Vaccine Action Plan for the Regional Hepatitis B Control Goal; preparing for a comprehensive regional integrated plan for prevention and control of viral hepatitis, including the setting of a regional goal and targets, in line with the global strategy
- Development of national hepatitis plans in every country, with targets and access to prevention and care for all patients (WHO, ELPA and other civil society organizations)
- Development of plans with all stakeholders and with budgets
- Strengthening networking and seek synergies
- ECDC: surveillance, monitoring, and development of tools and guidelines for prevention and control
- VHPB to provide a forum for exchange of information about mechanisms to reduce prices and models for existing price negotiations
- The role of antiviral agents in prevention
What do you expect from the countries

- Commitment to and monitoring implementation of the European Vaccine Action Plan and the hepatitis B goal
- Leadership of Member States in design and implementation of national plans
- Advocacy at supranational level
- Provision of national information and data, collaboration through networks
- Increase public health capacity for prevention and control of viral hepatitis, including surveillance